These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 23817699)

  • 1. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
    Goldfine AB; Fonseca V; Jablonski KA; Chen YD; Tipton L; Staten MA; Shoelson SE;
    Ann Intern Med; 2013 Jul; 159(1):1-12. PubMed ID: 23817699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Goldfine AB; Fonseca V; Jablonski KA; Pyle L; Staten MA; Shoelson SE;
    Ann Intern Med; 2010 Mar; 152(6):346-57. PubMed ID: 20231565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes.
    Faghihimani E; Aminorroaya A; Rezvanian H; Adibi P; Ismail-Beigi F; Amini M
    Acta Diabetol; 2013 Aug; 50(4):537-43. PubMed ID: 21938543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).
    Goldfine AB; Buck JS; Desouza C; Fonseca V; Chen YD; Shoelson SE; Jablonski KA; Creager MA;
    Diabetes Care; 2013 Dec; 36(12):4132-9. PubMed ID: 24130358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins.
    Hauser TH; Salastekar N; Schaefer EJ; Desai T; Goldfine HL; Fowler KM; Weber GM; Welty F; Clouse M; Shoelson SE; Goldfine AB;
    JAMA Cardiol; 2016 Jul; 1(4):413-23. PubMed ID: 27438317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statin-treated cardiovascular disease: A 30-month randomized placebo-controlled trial.
    Salastekar N; Desai T; Hauser T; Schaefer EJ; Fowler K; Joseph S; Shoelson SE; Goldfine AB;
    Diabetes Obes Metab; 2017 Oct; 19(10):1458-1462. PubMed ID: 28295931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes.
    Faghihimani E; Aminorroaya A; Rezvanian H; Adibi P; Ismail-Beigi F; Amini M
    Endocr Pract; 2012; 18(6):826-33. PubMed ID: 22784842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.
    Koska J; Ortega E; Bunt JC; Gasser A; Impson J; Hanson RL; Forbes J; de Courten B; Krakoff J
    Diabetologia; 2009 Mar; 52(3):385-93. PubMed ID: 19104769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes.
    Goldfine AB; Silver R; Aldhahi W; Cai D; Tatro E; Lee J; Shoelson SE
    Clin Transl Sci; 2008 May; 1(1):36-43. PubMed ID: 19337387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance.
    Goldfine AB; Conlin PR; Halperin F; Koska J; Permana P; Schwenke D; Shoelson SE; Reaven PD
    Diabetologia; 2013 Apr; 56(4):714-23. PubMed ID: 23370525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
    Barzilay JI; Jablonski KA; Fonseca V; Shoelson SE; Goldfine AB; Strauch C; Monnier VM;
    Diabetes Care; 2014 Apr; 37(4):1083-91. PubMed ID: 24255104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salsalate improves glycemia and inflammatory parameters in obese young adults.
    Fleischman A; Shoelson SE; Bernier R; Goldfine AB
    Diabetes Care; 2008 Feb; 31(2):289-94. PubMed ID: 17959861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics.
    Alderete TL; Sattler FR; Richey JM; Allayee H; Mittelman SD; Sheng X; Tucci J; Gyllenhammer LE; Grant EG; Goran MI
    Obesity (Silver Spring); 2015 Mar; 23(3):543-51. PubMed ID: 25644856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
    Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
    Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus.
    Schwartz SL; Rendell M; Ahmann AJ; Thomas A; Arauz-Pacheco CJ; Welles BR
    Clin Ther; 2008 Jun; 30(6):1081-8. PubMed ID: 18640464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.